CU20220044A7 - Receptor de células t restringido por hla de la clase i contra ras con mutación g12d - Google Patents
Receptor de células t restringido por hla de la clase i contra ras con mutación g12dInfo
- Publication number
- CU20220044A7 CU20220044A7 CU2022000044A CU20220044A CU20220044A7 CU 20220044 A7 CU20220044 A7 CU 20220044A7 CU 2022000044 A CU2022000044 A CU 2022000044A CU 20220044 A CU20220044 A CU 20220044A CU 20220044 A7 CU20220044 A7 CU 20220044A7
- Authority
- CU
- Cuba
- Prior art keywords
- hla
- tcr
- contra
- ras
- mutation
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title 1
- 102200006539 rs121913529 Human genes 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 235000018102 proteins Nutrition 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/00041—Use of virus, viral particle or viral elements as a vector
- C12N2740/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
Abstract
<p>Se describe un receptor de célula T (TCR) aislado y purificado, donde el TCR tiene especificidad antigénica por una secuencia de aminoácidos RAS humana mutada con una sustitución de glicina en la posición 12 con ácido aspártico presentada por una molécula de antígeno leucocitario humano (HLA) de la Clase I. También se proporcionan polipéptidos y proteínas relacionadas, así como los ácidos nucleicos relacionados, vectores de expresión recombinantes y composiciones farmacéuticas. También se describen métodos para producir el TCR, el polipéptido y la proteína</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975544P | 2020-02-12 | 2020-02-12 | |
| PCT/US2021/017794 WO2021163434A1 (en) | 2020-02-12 | 2021-02-12 | Hla class i-restricted t cell receptors against ras with g12d mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20220044A7 true CU20220044A7 (es) | 2023-06-13 |
Family
ID=74860472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2022000044A CU20220044A7 (es) | 2020-02-12 | 2021-02-12 | Receptor de células t restringido por hla de la clase i contra ras con mutación g12d |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230080742A1 (es) |
| EP (1) | EP4103597A1 (es) |
| JP (1) | JP2023528112A (es) |
| KR (1) | KR20220143867A (es) |
| CN (1) | CN115279784A (es) |
| AU (1) | AU2021221138A1 (es) |
| BR (1) | BR112022015888A2 (es) |
| CA (1) | CA3168015A1 (es) |
| CL (1) | CL2022002208A1 (es) |
| CO (1) | CO2022012922A2 (es) |
| CU (1) | CU20220044A7 (es) |
| GB (1) | GB2609760A (es) |
| IL (1) | IL295252A (es) |
| MX (1) | MX2022009654A (es) |
| TW (1) | TW202140536A (es) |
| WO (1) | WO2021163434A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230084524A (ko) * | 2020-10-02 | 2023-06-13 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체 |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| CA2968399A1 (en) * | 2014-11-26 | 2016-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mutated kras t cell receptors |
| CN108395479B (zh) * | 2017-02-06 | 2021-07-16 | 高军 | 一种有关kras基因突变的t细胞受体 |
| KR20200115484A (ko) * | 2017-12-04 | 2020-10-07 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 돌연변이 ras에 대한 hla 클래스 i-제한 t 세포 수용체 |
-
2021
- 2021-02-12 MX MX2022009654A patent/MX2022009654A/es unknown
- 2021-02-12 AU AU2021221138A patent/AU2021221138A1/en active Pending
- 2021-02-12 BR BR112022015888A patent/BR112022015888A2/pt unknown
- 2021-02-12 KR KR1020227031175A patent/KR20220143867A/ko unknown
- 2021-02-12 JP JP2022548811A patent/JP2023528112A/ja active Pending
- 2021-02-12 GB GB2211733.7A patent/GB2609760A/en active Pending
- 2021-02-12 CA CA3168015A patent/CA3168015A1/en active Pending
- 2021-02-12 TW TW110105194A patent/TW202140536A/zh unknown
- 2021-02-12 CU CU2022000044A patent/CU20220044A7/es unknown
- 2021-02-12 IL IL295252A patent/IL295252A/en unknown
- 2021-02-12 EP EP21710730.9A patent/EP4103597A1/en active Pending
- 2021-02-12 CN CN202180014038.2A patent/CN115279784A/zh active Pending
- 2021-02-12 WO PCT/US2021/017794 patent/WO2021163434A1/en unknown
- 2021-02-12 US US17/799,163 patent/US20230080742A1/en active Pending
-
2022
- 2022-08-12 CL CL2022002208A patent/CL2022002208A1/es unknown
- 2022-09-12 CO CONC2022/0012922A patent/CO2022012922A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB202211733D0 (en) | 2022-09-28 |
| BR112022015888A2 (pt) | 2022-10-11 |
| CA3168015A1 (en) | 2021-08-19 |
| GB2609760A (en) | 2023-02-15 |
| KR20220143867A (ko) | 2022-10-25 |
| US20230080742A1 (en) | 2023-03-16 |
| TW202140536A (zh) | 2021-11-01 |
| CO2022012922A2 (es) | 2022-10-21 |
| AU2021221138A1 (en) | 2022-09-01 |
| CL2022002208A1 (es) | 2023-06-02 |
| EP4103597A1 (en) | 2022-12-21 |
| JP2023528112A (ja) | 2023-07-04 |
| WO2021163434A1 (en) | 2021-08-19 |
| MX2022009654A (es) | 2022-10-20 |
| WO2021163434A8 (en) | 2022-09-01 |
| CN115279784A (zh) | 2022-11-01 |
| IL295252A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20220044A7 (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación g12d | |
| EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
| PE20190477A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
| Bjorkman et al. | Structure of the human class I histocompatibility antigen, HLA-A2 | |
| AR112902A1 (es) | Receptores de células t restringidas a hla de clase ii contra ras mutado | |
| CL2019003311A1 (es) | Nuevos péptidos (seq id no:82) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124) | |
| CL2018002648A1 (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer | |
| BR112016015512A2 (pt) | proteínas quiméricas de fator viii e suas utilizações | |
| AR071874A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
| CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
| AR086982A1 (es) | Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase i | |
| CL2023000562A1 (es) | Proteínas de unión a antígeno que se unen específicamente a mage-a | |
| Karapetyan et al. | TCR fingerprinting and off-target peptide identification | |
| CY1108538T1 (el) | Χιμαιρικα πεπτιδια β-αμυλοειδους | |
| Purcell et al. | Association of stress proteins with autoantigens: a possible mechanism for triggering autoimmunity? | |
| BR112022015897A2 (pt) | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v | |
| Spodzieja et al. | Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses | |
| CR20200170A (es) | Receptores de células t que reconocen p53 mutado | |
| BR112023003526A2 (pt) | Proteínas de fusão de coronavírus imunogênicos e métodos relacionados | |
| Willimsky et al. | In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo | |
| CY1117283T1 (el) | Σταθερα μονομερη και ολιγομερη αμυλοειδους βητα | |
| ES2561497T3 (es) | Ligandos monovalentes del receptor CD28 humano | |
| Finton et al. | ARTEMIS: a novel mass-spec platform for HLA-restricted self and disease-associated peptide discovery | |
| Weiss et al. | Covalent HLA-B27/peptide complex induced by specific recognition of an aziridine mimic of arginine. | |
| AR044603A1 (es) | Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones |